These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14973205)

  • 1. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 2. Diverse effects of infliximab and etanercept on T lymphocytes.
    Sieper J; Van Den Brande J
    Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials.
    Rahimi R; Nikfar S; Abdollahi M
    Biomed Pharmacother; 2007 Jan; 61(1):75-80. PubMed ID: 17184965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab induced T lymphocyte apoptosis in Crohn's disease.
    van den Brande J; Hommes DW; Peppelenbosch MP
    J Rheumatol Suppl; 2005 Mar; 74():26-30. PubMed ID: 15742461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 8. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Sandborn WJ; Hanauer SB; Katz S; Safdi M; Wolf DG; Baerg RD; Tremaine WJ; Johnson T; Diehl NN; Zinsmeister AR
    Gastroenterology; 2001 Nov; 121(5):1088-94. PubMed ID: 11677200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease.
    van Deventer SJ
    Gastroenterology; 2001 Nov; 121(5):1242-6. PubMed ID: 11677219
    [No Abstract]   [Full Text] [Related]  

  • 11. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 12. [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
    Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
    Farnsworth NN; George SJ; Hsu S
    Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
    [No Abstract]   [Full Text] [Related]  

  • 14. [Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH].
    Tilg H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W;
    Z Gastroenterol; 2004 Oct; 42(10):1256-63. PubMed ID: 15508068
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biological compounds in the treatment of Crohn's disease].
    Dinari G
    Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
    Berg PA
    Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
    [No Abstract]   [Full Text] [Related]  

  • 18. New biologic agents: a critical appraisal.
    Sands BE
    Curr Gastroenterol Rep; 1999 Dec; 1(6):470-5. PubMed ID: 10980988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
    Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn's disease.
    Rosenstiel P; Agnholt J; Kelsen J; Medici V; Waetzig GH; Seegert D; Schreiber S
    Gut; 2005 Feb; 54(2):314-5; author reply 316-6. PubMed ID: 15647208
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.